1stOncology™: Cancer Intelligence Service – Page 14383 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

ORIC Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

On May 28, 2019 ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance, reported that Jacob Chacko, MD, Chief Executive Officer, will present and host one-on-one investor meetings at the Jefferies 2019 Global Healthcare Conference held June 4-7th at the Grand Hyatt in New York (Press release, ORIC Pharmaceuticals, MAY 28, 2019, View Source [SID1234536616]). Dr. Chacko will present on Thursday, June 6th at 8:30am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

On May 28, 2019 IDEAYA Biosciences, Inc. (Nasdaq:IDYA) reported the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $10.00 per share (Press release, Ideaya Biosciences, MAY 28, 2019, View Source [SID1234536615]). The gross proceeds from the offering were $57.5 million before deducting underwriting discounts, commissions and estimated offering expenses. This includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock from the company at the public offering price, less underwriting discounts and commissions. All of the shares of common stock were offered by IDEAYA Biosciences. The shares commenced trading on the Nasdaq Global Select Market on May 23, 2019, under the ticker symbol "IDYA".

J.P. Morgan, Citigroup and Jefferies acted as joint book-running managers for the offering.

A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on May 22, 2019. The offering is being made only by means of a prospectus, copies of which may be obtained from: J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 866-803-9204, or by email at [email protected]; Citigroup, by mail at Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146; or Jefferies, by mail at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery

On May 28, 2019 Harbour BioMed reported a worldwide multi-year license agreement with a Top-Ten, global pharmaceutical leader in immunology and immuno-oncology to discover, develop, and commercialize biologic therapeutics using Harbour’s patented HCAb transgenic mouse platform (Press release, Harbour BioMed, MAY 28, 2019, View Source [SID1234536613]). The HCAb platform generates novel, fully human heavy chain only antibodies to accelerate the discovery and development of advanced biologic therapeutics, especially single domain antibodies, bi-specific and multi-specific antibodies, and CAR-Ts.

"Drug discovery in the burgeoning fields of immuno-oncology and immunotherapy is relying increasingly on advanced biological approaches to selectively attack one or more immune targets and modulate the immune system to treat cancer and other diseases," said Dr. Jingsong Wang, CEO of Harbour BioMed. "The HCAb platform is emerging as a powerful technology to enable next generation biologic discovery for our internal portfolio and a select group of licensing partners. This new license agreement, with one of the world’s leading pharmaceutical companies, is a significant endorsement of our approach."

Under the terms of the agreement, Harbour BioMed will receive an upfront payment and will be further eligible to receive a combination of development and sales related milestone payments and royalties. Specific financial details were not disclosed. Harbour BioMed signed the non-exclusive license through its wholly-owned subsidiary, Harbour Antibodies HCAb BV.

Merck Announces Third-Quarter 2019 Dividend

On May 28, 2019 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that the Board of Directors has declared a quarterly dividend of $0.55 per share of the company’s common stock for the third quarter of 2019 (Press release, Merck & Co, MAY 28, 2019, View Source [SID1234536612]). Payment will be made on July 8, 2019 to shareholders of record at the close of business on June 17, 2019.

Ayala Pharmaceuticals Raises $30 Million in Series B Financing

On May 28, 2019 Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically defined, reported the successful completion of a $30 million Series B financing (Press release, Ayala Pharmaceuticals, MAY 28, 2019, View Source [SID1234536611]).

The investment was led by Novartis with participation from SBI JI Innovation Fund and all existing investors, including Israel Biotech Fund, aMoon and Harel Insurance & Finance Group. The new capital will fuel Ayala’s plans to advance the clinical development of lead product candidate AL101, a pan-Notch inhibitor that is currently being evaluated for adenoid cystic carcinoma (ACC). The company intends to advance the phase 2 study in ACC and initiate a phase 2 clinical trial in triple negative breast cancer (TNBC).

"The strategic investment by Novartis coupled with the continued support from our investors in this round underscores the potential for both AL101 and AL102, pan-Notch inhibitors being investigated in patient populations with high unmet needs," said Roni Mamluk, Ph.D., Chief Executive Officer at Ayala Pharmaceuticals. "With this funding we are well positioned to complete the ongoing phase 2 study of AL101 in ACC and begin a phase 2 study with AL101 as a targeted therapy for patients living with TNBC bearing Notch activating mutations/fusions."

Ayala Pharmaceuticals is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with studies underway in solid tumors (AL101) and in hematologic malignancies (AL102) and in collaboration with Novartis in multiple myeloma.

The U.S. Food and Drug Administration’s Office of Orphan Products Development recently granted Orphan Drug Designation to AL101 for the potential treatment of ACC.

About AL101
AL101 is a gamma secretase inhibitor developed as a Notch inhibitor for oncology indications. Notch signaling pathway plays an important role in tumorigenesis in several solid and hematological malignancies. Upon ligand binding of the Notch receptor, an important step in the activation of Notch receptors is cleavage by gamma secretase, which frees the Notch intracellular signaling domain.

AL101 is currently in Phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY). For additional information about the AL101 ACCURACY clinical trial, please go to www.clinicaltrials.gov. Interested patients and physicians can contact Medical Affairs at Ayala Pharmaceuticals for more information at: [email protected] or call +1-857-444-0553.